MassHealth and the Massachusetts Department of Mental Health are writing to you about the prescribing of paliperidone (Invega®) for some of your MassHealth patients. We hope that this information is useful to you and your patient(s).
An extensive review of the literature does not support any clinically significant differences between paliperidone and risperidone. The two medications share a very similar pharmacological structure and profile. Typically, when medications are so structurally similar, a “head-to-head” trial is considered the “gold standard” for identifying differences between them. In this instance, no such studies have been conducted.
We have attached a list of your MassHealth patients who are currently prescribed paliperidone. Please review your cases carefully, and as clinically appropriate, reconsider continuing treatment with paliperidone, a much more costly product than risperidone.
Thank you for joining us in this important and focused effort to help ensure that our members receive medically necessary prescriptions that are safe and effective, and result in high quality and cost-effective care.